Intrauterine contraception among women living with human immunodeficiency virus a randomized controlled trial

Obstetrics and Gynecology

Volumn 126, Issue 5, 2015, Pages 928-934

  Kakaire, Othman ^a   Byamugisha, Josaphat Kayogoza ^b   Tumwesigye, Nazarius Mbona ^b   Gemzell Danielsson, Kristina ^b  

^a MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; COTRIMOXAZOLE; MEDROXYPROGESTERONE ACETATE; CONTRACEPTIVE AGENT; LEVONORGESTREL;

ABDOMINAL PAIN; ACNE; ADULT; ADVERSE OUTCOME; AMENORRHEA; ANTIVIRAL THERAPY; ARTICLE; BACKACHE; BLOATING; BODY WEIGHT DISORDER; COMPARATIVE EFFECTIVENESS; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; COPPER INTRAUTERINE DEVICE; DEVICE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEADACHE; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTENTION TO TREAT ANALYSIS; INTRAUTERINE DEVICE EXPULSION; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; LIBIDO DISORDER; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MENORRHAGIA; MUSCLE CRAMP; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UGANDA; VAGINA DISCHARGE; COMPARATIVE STUDY; PATIENT COMPLIANCE; PREGNANCY; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADULT; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES, COPPER; LEVONORGESTREL; PATIENT COMPLIANCE; PREGNANCY; YOUNG ADULT;

EID: 84945133485     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000001087     Document Type: Article

References (31)

1. Lawani LO, Onyebuchi AK, Iyoke CA. Dual method use for protection of pregnancy and disease prevention among HIV-infected women in South East Nigeria. BMC Womens Health 2014;14:39.
2. World Health Organization. PMTCT strategic vision 2010-2012, World Health Organization. Geneva (Switzerland): World Health Organization; 2010.
3. McCoy SI, Buzdugan R Ralph LJ, Mushavi A Mahomva A Hakobyan A, et al. Unmet need for family planning, contraceptive failure, and unintended pregnancy among HIV-infected and HIV-uninfected women in Zimbabwe. PLoS One 2014;9:e105320.
4. Kaida A, Laher F, Strathdee SA, Money D, Janssen PA, Hogg RS, et al. Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services. PLoS One 2010;5:e13868.
5. Perry SH, Swamy P, Preidis GA, Mwanyumba A, Motsa N, Sarero HN. Implementing theJadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies. AIDS 2014; 28:791-3.
6. Robinson JA, Jamshidi R Burke AE. Contraception for the HIV-positive woman: a review of interactions between hormonal contraception and antiretroviral therapy. Infect Dis Obstet Gynecol 2012;2012:890160.
7. Heffron R Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis 2012;12:19-26.
8. Morrison CS, Chen PL, Kwok C, Baeten JM, Brown J, Crook AM, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. PLoS Med 2015;12:e1001778.
9. Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol 2011;117:705-19.
10. Sinei SK, Morrison CS, Sekadde-Kigondu C, Allen M, Kokonya D. Complications of use of intrauterine devices among HIV-1-infected women. Lancet 1998;351:1238-41.
11. Morrison CS, Sekadde-Kigondu C, Sinei SK, Weiner DH, Kwok C, Kokonya D. Is the intrauterine device appropriate contraception for HIV-1-infected women? BJOG 2001;108:784-90.
12. Richardson BA, Morrison CS, Sekadde-Kigondu C, Sinei SK Overbaugh J, Panteleeff DD, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 1999;13:2091-7.
13. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 2007;197:144.e1-8.
14. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel-and copper-releasing intrauterine devices. Obstet Gynecol 1991;77:261-4.
15. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, PaavonenJ. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. AmJ Obstet Gynecol 2011;204:126.e1-4.
16. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women-effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006;21: 2857-61.
17. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
18. Ministry of Health. Sexually transmitted infections treatment guidelines for use by operational level health workers in Uganda. 2003. Available at: aim.jsi.com/Docs/sti-treatment-guideline- hcp.pdf. Retrieved May 24, 2015.
19. Centers for Disease Control and Prevention. U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use. 2nd ed. 2013. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm. Retrieved June 26, 2015.
20. Grunloh DS, Casner T, Secura GM, Peipert JF, Madden T. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol 2013;122:1214-21.
21. Cea Soriano L, Wallander MA, Andersson S, Filonenko A, Garcia Rodriguez LA. The continuation rates of long-acting reversible contraceptives in UK general practice using data from The Health Improvement Network. Pharmacoepidemiol Drug Saf 2015;24:52-8.
22. Sivin I, Stern J, Diaz J, Diaz MM, Faundes A, el Mahgoub S, et al. Two years of intrauterine contraception with levonorges-trel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices. Contraception 1987;35:245-55.
23. Sivin I, el Mahgoub S, McCarthy T, Mishell DR Jr, Shoupe D, Alvarez F, et al. Long-term contraception with the levonorges-trel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study. Contraception 1990;42: 361-78.
24. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-13.
25. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72.
26. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
27. Heinemann K, Reed S, Moehner S, Do Minh T. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices. Contraception 2015;91:280-3.
28. Kapur A, Kumar S. Contraceptive effectiveness of levonorges-trel releasing intrauterine system. Med J Armed Forces India 2008;64:140-2.
29. Stephenson R, Vwalika B, Greenberg L, Ahmed Y, Vwalika C, Chomba E, et al. A randomized controlled trial to promote long-term contraceptive use among HIV-serodiscordant and concordant positive couples in Zambia. J Womens Health (Larchmt) 2011;20:567-74.
30. Haddad LB, Cwiak C, Jamieson DJ, Feldacker C, Tweya H, Hosseinipour M, et al. Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogester-one acetate. Contraception 2013;88:737-43.
31. Udigwe G, Mbachu I, Onyegbule O, Oguaka V. Use of Condoms among Human Immunodeficiency Virus Positive Women Attending Antenatal Clinic in Nnewi, South East Nigeria. Ann Med Health Sci Res 2014;4:687-91.